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Antiphospholipid syndrome is one type of immunological diseases which may be primary or secondary characterized by repeated
thrombosis that it may be called “sticky blood syndrome”. Although a well-known disease in gynecology, there is no suﬃcient data
in pediatrics ﬁeld; so we see that it is important to discuss this interesting case.
1.Introduction
Antiphospholipd syndrome is a disorder of recurrent vas-
cular thrombosis, pregnancy loss, and thrombocytopenia
associated with persistently raised levels of antiphospholipid
antibodies [1]. It may be primary, occurs alone or secondary,
associated with other autoimmune or rheumatic diseases,
also known as Hughes syndrome, as described by Dr.
Graham Hughes in 1983. In recent years, the features of
antiphospholipid syndrome have been increasingly recog-
nized in children [2].
2.Objective
We discuss a case with diﬀerent presentation. It was diag-
nosed at ﬁrst as hemolytic uremic syndrome and passed
through diﬀerent other presentations which fulﬁlled the
diagnostic criteria of antiphospholipid syndrome.
3. Case Presentation
The case was a female female patient 13 years old, 1st kid
of a low socioeconomic state family, from Zagazig. The
condition started (May 2007) by acute onset of vomiting not
respondingtoanymedicationfollowedon2nddaybyvaginal
bleeding for 13 days. She was referred to insurance hospital
where they discovered on clinical examination, jaundice and
pallor too. The patient was then referred to our hematology
unit where complaining of dark colored urine, puﬀy eyelid,
and on examination there was purpura on abdominal, and
investigation at that time revealed the following.
CBC: Hb 5.7gm\dL, RC 21%, platelet 28000, serum
Creatinine 2mg\dL, blood Urea 113mg\dL, Coombs test
both direct and indirect were negative, Total billruibin
2.2mg\dL, direct 0.2mg\dL, ESR 75, Urine analysis showed
RBC’s over 100.
Our diﬀerential diagnosis at that level was as follows:
(1) hemolytic uremic syndrome,
(2) autoimmune hemolytic anemia,
(3) immunological disease, for example, SLE,
(4) TTP (thrombotic thrombocytopenic purpura),
(5) chronic hemolytic anemia on exacerbation,
(6) post infection, for example, HBV.
So we performed next investigations: blood ﬁlm showed
fragmented red cells, Coombs test again direct and indirect
were negative, Osmotic fragility was negative, Hemoglobin
electrophoresis was normal, ANA negative, Anti-double-
strand DNA negative, Abdominal US enlarged kidneys with
mild splenomegaly, Hepatitis markers HBV weak positive
(HBS Ag) by PCR negative, C3 normal. So diagnosis of
hemolytic uremic syndrome was the most likely diagnosis at2 International Journal of Nephrology
that level with raising Creatinine to 10.5mg\dL, dialysis was
initiated (via subclavian catheter), plus supportive blood and
platelet transfusion and Electrolytes support.
Actuallyourpatientshowedslowresponsetodialysisthat
she was dialysis to the extend dependent for 7 weeks; GFR
by DTPA at that time was 15mL\mint\1.73m. So AVF was
done.
Apart from 3 admissions to ICU with malignant hyper-
tension, no other systems were aﬀected in the next 7 weeks.
Blood pressure was diﬃcult to control because Dina was on
4 antihypertensives.
So it is a type of resistant HUS. We gave plasma
transfusion repeatedly to cut oﬀ the circuit of pathogenesis;
actually it was a great surprise that Dina began to be oﬀ
dialysis, with normal CBC.
The patient was discharged on conservative management
of CRF and a close followup twice weekly was done.
Investigationsonfollowupafter2monthsofadmission(July
2007) showed CBC RC 3%, Hb 9gm\dL, Platelet 224,000,
Urea 42 mg\dL, and Creatinine 1.3mg\dL.
The patient readmitted 3 weeks later with acute pallor
and jaundice again with purpura and hypertension with
palpitation.
Investigations at that time (August 2007) showed the
following results: RC 7.8%, Hb 7.6gm\dL, Platelet 94,000,
Coombs negative, Creatinine 4.9mg\d L ,U r e a1 6 7m g \dL,
Urine RBCS over 100, C3 consumed (0.5), ANA and Anti-
double-strand DNA were negative, ANCA negative, ESR 85
1st hour, 126 2nd hour. Bone marrow biopsy was done
and revealed hyperactive bone marrow with no abnormal
or megakaryocytic changes. ECG showed sinus tachycardia.
echocardiography showed grade 3\4 miteral regurgitation,
grade 1\4 Aortic regurgitation, pulmonary hypertension,
and moderate pericardial eﬀusion.
Plasmapheresis was initiated 4 sessions at one week with
no improvement so redialysis was repeated.
One week later the patient complained of abdominal
pain, abdominal US, right kidney enlargement for Doppler
study, and right renal artery blunted systolic ﬁlling denote
obstruction at subsegmental branching.
Renal biopsy was done revealing, Microangiopathic
glomerulonephritis HUS versus other vasculitis.
Our diﬀerential diagnosis at this level was:
(1) SLE,
(2) other types of vasculitis,
(3) 2ry antiphospholipid syndrome,
(4) TTP,
(5) other cause (protein S.C deﬁciency),
(6) 1ry antiphospholipid syndrome.
Anticardiolipin was done and it was positive.
So diagnosis of antiphospholipid syndrome was done
and treatment was initiated as follows: steroid was initiated
in September 2007. Anticoagulation heparin followed by low
molecular weight heparin was given as well as antiplatelet,
Cytotoxic in the form of cyclophosphamide 2 pulses I.V.
monthly apart.
After two weeks Hemolysis regressed, but renal function
was the same, GFR 30mL\mint\1.73m (improved). But the
patient developed new signs of vascular aﬀection in the form
of Lived reticularis on abdominal wall and leg with repeated
chest pain.
NotethatthepatientwasonregulardialysisthroughAVF,
blood pressure ﬂuctuations were on the high level always (so
stoppage of anticoagulant was done), and antidepressant was
added; blood pressure was controlled by it plus using one
antihypertensive only but the patient lost 9kg in the next 6
months.
She complained of recurrent massive pericardial eﬀu-
sions and responded to daily dialysis for 15 days each time
f o r4t i m e sw i t hs t o p p a g eo fa n t i c o a g u l a n t .
Intravenousimmunoglobulinwasgiven5daysaweekfor
three weeks, but unfortunately with no response as regards
hemolysis or C3 level.
ReinvestigatingforACL,ANA,Anti-douple-strandDNA,
ANCA, and all four tests were negative. And two weeks later
repeated ACL was done and was negative.
The patient was on the same management with gradual
decrease of steroid because the only response was raising C
3 level without clinical response for 3 months; on the other
hand, hypocalcaemia and other signs of side eﬀects began.
In November 2007, AVF thrombosis proved by Doppler
recanalisation was done.
In December 2007, echocardiography was done for
repeated chest pain with normal ECG showing unequal
septal movement evident of myocardial infarction. Unfortu-
nately, cardiac enzymes were not available at that time.
In January 2008, sever chest infection followed by
hemoptysis occurred. Tuberculin test done with double
dose was negative and CT chest revealed wedge pulmonary
infarction.
In February 2008, head nodding and static tremors,
possibility of Parkinson’s (basal ganglia vascular aﬀection)
occured, but the result of MRI came to be frontal lobe
atrophy from repeated infarctions mostly.
In March 2008, AVF rethrombosis occured and it was
documented by Doppler but after 24 hours of detection
of thrombosis, ﬁstula leakage and emergency closure were
done.
In April 2008, the patient developed sever chest pain
diagnosed as pulmonary infarction for which she was
admitted to intensive care unit and unfortunately died.
4. Discussion
The description of antiphospholipid syndrome has been one
of the most striking developments in the ﬁeld of immunol-
ogy in the last two decades [1] the earliest descriptions of the
association between a circulating anticoagulant and vascular
thrombosis in pediatric population are those of Olive et al.
1979 [3].
Our case had the following positive clinical data:
hemolytic anemia, thrombocytopenia, hematuria with
impaired kidney function, interarenal vascular occlusion,
pulmonary infarction, cardiac infarction, valvular lesion,International Journal of Nephrology 3
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Figure 1: Renal biopsy showing Microangiopathic glomerulonephritis.
recurrent pericardial eﬀusion, AVF thrombosis, and neu-
rological insult.
And the case had the positive laboratory data as follows:
ACL positive once, ANA, Anti-double-stranded DNA nega-
tive,ANCAnegative,C3consumed,documentedthrombosis
(interarenal, intraglomular, pulmonary, AVF, cardiac, CNS),
and normal PT, PTT.
For diagnosis of antiphospholipid syndrome, the patient
should fulﬁll the diagnostic preliminary criteria by Sapporo
which was proposed in 1998 one clinical plus one lab [1, 4].
(a) Clinical criteria are as follows:
(1) vascular occlusion artery, vein or minute vessels
in tissue or organ with no inﬂammatory reac-
tion around,
(2) pregnancy related.
(b) Laboratory criteria were as follows:
(1) ACL AB IgG or IgM positive in two separate
samples 6 weeks apart,
(2) lupus anticoagulant AB positive in two separate
samples 6 weeks apart.
AllcriterianeednottobemettomakeadiagnosisofAPS.
Catastrophic antiphospholipids syndrome (CAPS) (Acc-
elerated form of APS with consequent multiorgan failure,
disturbance at small vessel level) hasinternational criteria for
classiﬁcation such as
(1) clinical evidence of vessel occlusions aﬀecting 3 or
more organs or systems,
(2) development of the manifestations simultaneously or
in less than a week,
(3) conﬁrmation by histopathology of small vessel occlu-
sion in at least one organ,
(4) serological conﬁrmation of the presence of APL (LA
and/or ACL).
N.B. The kidney is the organ most commonly aﬀected
[5].
In our case the patient fulﬁlled criteria of a catas-
trophic antiphospholipid syndrome as the repeated ACL was
Figure 2: AVF rethrombosis and impending rupture.
negative, but our patient showed multiorgan failure, and
there is small vessel aﬀection as those appearing in renal
biopsy (Microangiopathic glemuleropathy). The main organ
aﬀected and one of the earliest organ aﬀections was the
kidney, and our case died after 11 months of diagnosis
although we start all kinds of therapy of APL.
Our case in clinical presentation showed veins aﬀec-
tion (Lived reticularis), arterial aﬀection (renal thrombotic
Microangiopathic, myocardial infarction, pulmonary infarc-
tion, and brain ischemic manifestation), and also showed
cardiac valve aﬀection which was also described in APL [1].
Our patient 1st presentation was hemolytic anemia and
thrombocytopenia which made us think that it is a case of
hemolytic uremic syndrome, but it was actually a spectrum
of clinical presentation of APL [2].
As regards diﬀerential diagnosis of our case, the main
diﬀerential diagnosis was to exclude SLE as recently the
presence of APL in lupus patients has been associated with
developmentofoccurrenceofneuropsychiatrymanifestation
[6] and ischemic Microangiopathic nephropathy [7], as
many studies reported prevalence of ACL and LA in juvenile
SLE ranges from 19%–87% and from 10%–62% [1], also
the possibility of transformation of 1ry APL to SLE after 6
months [1]. So we repeatedly sample our patient for ANA
Anti-double-stranded DNA and it was negative all through
till her death raising the possibility of 1ry APL rather than
2ry APL of SLE but this didnnot exclude the possibility of
lupus-like syndrome.4 International Journal of Nephrology
AsregardsmanagementofAPL,beingsymptomaticAPL,
that is, APL positive patient with thrombosis, it needs the
following:
(1) anticoagulant like other cases with thrombosis,
although the duration and intensity of antithrom-
botic therapy are not yet clearly established [8]. We
started low molecular weight heparin followed by
warfarin, but we needed to stop this treatment for
many times because of uncontrolled hypertension or
pericardial eﬀusion;
(2) high doses of corticosteroid, cyclophosphamide,
Intravinous immunoglobulin, and Plasmapheresis as
well as hemodialysis all were tried as all are rec-
ommended in life-threatening APL or catastrophic
antiphospholipid [9];
(3) although we gave many modalities of treatment, we
lost our patient in a severe attach of pulmonary
infarction and this showed us the important and the
aggressive form of this disease, as high mortality—up
to 48% despite antithrombotic therapy—had been
reported in many studies [1, 5, 9].
5. Conclusion
APL is recognized increasingly as a leading cause of vas-
cular thrombosis in pediatric population; also catastrophic
antiphospholipid syndrome should take much care and
recognition by pediatricians being one of severe and rabidly
fatal disease; we saw to share this case and we suggest further
studies about diagnosis, presentation, and management of
this serious disease.
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